PMID- 26549576
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20220408
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 32
IP  - 2
DP  - 2016
TI  - A discrete-choice experiment to quantify patient preferences for frequency of 
      glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 
      diabetes.
PG  - 251-62
LID - 10.1185/03007995.2015.1117433 [doi]
AB  - OBJECTIVE: Understanding patients' preferences for attributes of injectable 
      antihyperglycemic regimens may improve patient satisfaction and medication 
      adherence. Our objective was to quantify the preferences of patients with type 2 
      diabetes mellitus (T2DM) for reducing the frequency of glucagon-like peptide-1 
      receptor agonist injections from once daily to once weekly. METHODS: A total of 
      643 respondents with a self-reported physician diagnosis of type 2 diabetes 
      completed a web-based discrete-choice experiment survey. The sample included four 
      prespecified subgroups: currently using exenatide once weekly (n = 150), 
      liraglutide once daily (n = 153), insulin (but not exenatide once weekly or 
      liraglutide) (n = 156), and no injectable treatment (n = 184). Device attributes 
      included type of injection device, needle size and pain, injection frequency, 
      refrigeration, and injection-site reactions. Random-parameters logit was used to 
      estimate the relative impact of device attributes on treatment choice for each 
      subgroup. RESULTS: In all subgroups, changing injection frequency from daily to 
      weekly (independent of the effect of injection frequency on preferences for other 
      attributes) was the most important predictor of treatment choice. Switching from 
      a longer and thicker needle to a shorter and thinner needle and eliminating 
      injection-site reactions were also statistically significant predictors of device 
      choice (P < 0.05). Exenatide once weekly users and those not currently using 
      injections were more likely to choose a treatment with characteristics similar to 
      exenatide once weekly. CONCLUSIONS: The treatment attribute most important to 
      patients choosing among hypothetical injectable treatments for T2DM was injection 
      frequency: patients preferred weekly over daily injections. LIMITATIONS: The 
      primary limitations of this study are that it included only a limited number of 
      attributes that may not reflect the full complexity of patient choices, diagnosis 
      was self-reported, and patients were recruited from an Internet panel and may not 
      be representative of the T2DM patient population.
FAU - Hauber, A Brett
AU  - Hauber AB
AD  - a a RTI Health Solutions, Research Triangle Park , NC , USA.
FAU - Nguyen, Hiep
AU  - Nguyen H
AD  - b b AstraZeneca, Fort Washington , PA , USA.
FAU - Posner, Joshua
AU  - Posner J
AD  - a a RTI Health Solutions, Research Triangle Park , NC , USA.
FAU - Kalsekar, Iftekhar
AU  - Kalsekar I
AD  - c c Johnson and Johnson , New Brunswick , NJ , USA (was with AstraZeneca at the 
      time this study was developed).
FAU - Ruggles, James
AU  - Ruggles J
AD  - b b AstraZeneca, Fort Washington , PA , USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151130
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 839I73S42A (Liraglutide)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Choice Behavior
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Administration Schedule
MH  - Exenatide
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Injections
MH  - Insulin/therapeutic use
MH  - Liraglutide/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Patient Preference
MH  - Peptides/*administration & dosage
MH  - Venoms/*administration & dosage
OTO - NOTNLM
OT  - Conjoint analysis
OT  - Discrete-choice experiment
OT  - GLP-1 receptor agonist
OT  - Injection
OT  - Preference
OT  - Type 2 diabetes mellitus
EDAT- 2015/11/10 06:00
MHDA- 2016/08/30 06:00
CRDT- 2015/11/10 06:00
PHST- 2015/11/10 06:00 [entrez]
PHST- 2015/11/10 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.1185/03007995.2015.1117433 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2016;32(2):251-62. doi: 10.1185/03007995.2015.1117433. Epub 
      2015 Nov 30.